Gastroenterology, Hepatology and Nutrition

Research

Information/Contact
Contact Information
Close
Division: 
Gastroenterology, Hepatology & Nutrition
Director: 
Joel E. Lavine, MD, PhD
Email: 
jl3553@columbia.edu
Phone: 
(212) 342-2962
Administrator: 
Lubna Shamsi, MPH
Phone: 
(212) 305-5831
Fax: 
(212) 342-5756
  • Contribution of Organ Size to Adaptive Thermogenesis during Caloric Restriction. Wei Shen, MD (NIH grant 1R01 1AG045761-01)
  • Prevalence of Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) in NYC: Fatty liver disease is the most common cause of liver disease in the pediatric population and is closely linked to the rise in obesity. Unfortunately, the diagnosis and staging of the NAFLD can only be made with liver biopsy, so it has been difficult to determine its true prevalence. This study will be using autopsy data from pediatric patients who succumbed to an accidental death to determine the prevalence of fatty liver disease in the New York City area. The project is funded by the New York Obesity Nutrition Research Center. Ali Mencin, MD (NY Obesity Nutrition Research Center - SLRHC CU11-0598)
  • Sex Differences in Statural Growth Impairment in Pediatric Patients with Crohn's Disease: This study investigates the etiology of differences in growth impairment in males compared with females with Crohn's disease. Neera Gupta, MD, MAS (Driscoll - K23DK077734)
  • Statural growth in pediatric patients with ulcerative colitis: This study evalutes growth in patients with ulcerative colitis. Neera Gupta, MD, MAS (NIDDK, RO1 pending)
  • Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study: We are a participating site in this multicenter clinical trial that will determine the response to standardized medical therapy and identify clinical, genetic, and immune markers that predict response to therapy in pediatric patients with ulcerative colitis. Neera Gupta, MD, MAS (NIDDK - U01DK095745)
  • Non-alcoholic fatty liver disease (NAFLD): To study the natural history, etiopathogenesis, epidemiology, histopathology imaging and treatment with xenobiotics of NAFLD. Joel Lavine, MD, PhD (NICHD-5R01 HD062489-02)
  • Role of Enteric nervous system and predisposition to Crohn's disease, Ulcerative Colitis and Necrotizing Enterocolitis: This grant aims to examine the effects of the density of enteric innervation on intestinal permeability, the innate immune system and the adaptive immune system. Kara Margolis, MD (NIH K08 - PA-11-193)
  • Role of gastrointestinal disorders in children with autism: This grant aims to examine the effects of the density of enteric innervation on intestinal permeability, the innate immune system and the adaptive immune system. Kara Margolis, MD (AGEA - CU11-3510)
  • FISH OIL FOR THE TREATMENT OF NON-ALCHOLIC FATTY LIVER DISEASE (NAFLD): The goal of this pediatric study is to determine if supplements of n-3 LCPUFA can improve elevated liver enzymes, plasma lipid levels, as well as attenuate insulin resistance in patients with fatty liver disease. Diana Volpert, MD, FAAP (GlaxoSmithKline)
  • Clinical Research on Nonalcoholic Fatty Liver Disease: These studies examine the natural history, etiopathogenesis, epidemiology, histopathology, imaging, treatment and development of biomarkers in fatty liver disease in children and adults. Joel Lavine, MD, PhD (NIH - 5U01DK061734-11)
  • A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease: This is a multicenter longitudinal study examining the safety and efficacy of biological modifiers in inflammatory bowel disease. Joel Lavine, MD, PhD (C0168Z02; CRD1 CU11-2532)
  • NAFLD Altered Drug Metabolism study: This study examines the metabolism of certain xenobiotics in children with biopsy proven NASH and matched controls. Joel Lavine, MD, PhD (NIH - NICHD- 5R01HD062489-02)
  • Intestinal Taste Perception and the Metabolic Syndrome: Sarah Taylor, MD will be working in the laboratory of Dr. Charles Zuker, PhD investigating the role of taste sensing in the mouse intestine. Sarah Taylor (NICHD/Pediatric National Scientific Development Award - PSDP / NICHD/K12HD000850-28)
  • The role of peripherally produced serotonin in energy metabolism: Dana Goldner will be working under the guidance of Dr. Gerard Karsenty, MD, PhD, investigating the role of peripherally produced serotonin in glucose and lipid metabolism. Dana Goldner (NICHD/Pediatric National Scientific Development Award - PSDP / NICHD/K12HD000850-28)
  • The trial, called Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children (CyNCh),will enroll 160 boys and girls ages 8 to 17 with nonalcoholic fatty liver disease (NAFLD). The participants will receive cysteamine or placebo by mouth twice a day for a year. There are no weight cutoffs or percentiles for the children participating in CyNCh. However, more than 90 percent of the children are expected to be overweight or obese. Participants need a baseline biopsy that confirms severe NAFLD to be eligible for the study. Children with poorly managed diabetes, heart disease, and other chronic liver diseases will be excluded. FUNDED BY THE NIDDK. CONTACT JOEL LAVINE.